Transcriptional regulation of the nada gene in neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup b vaccine

Infection and Immunity

Volumn 81, Issue 2, 2013, Pages 560-569

  Fagnocchi, Luca ^a   Biolchi, Alessia ^a   Ferlicca, Francesca ^a   Boccadifuoco, Giuseppe ^a   Brunelli, Brunella ^a   Brier, Sébastien ^a   Norais, Nathalie ^a   Chiarot, Emiliano ^a   Bensi, Giuliano ^a   Kroll, J Simon ^b   Pizza, Mariagrazia ^a   Donnelly, John ^a,c   Giuliani, Marzia Monica ^a   Delany, Isabel ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b Wright Fleming Institute   (United Kingdom)

^c Prog Appropriate Technol Hlth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; BACTERIAL PROTEIN; MENINGOCOCCUS VACCINE; NADA PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP B; RATS; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84873022548     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01085-12     Document Type: Article

References (40)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388.
2. Tinsley C, Nassif X. 2001. Meningococcal pathogenesis: at the boundary between the pre- and post-genomic eras. Curr. Opin. Microbiol. 4:47-52.
3. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Mainassara HB, Tenebray B, Kairo KK, Giorgini D, Chanteau S. 2007. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 44:657-663.
4. Jarvis GA, Vedros NA. 1987. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect. Immun. 55: 174-180.
5. Stephens DS, Greenwood B, Brandtzaeg P. 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369:2196-2210.
6. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839.
7. Esposito S, Vesikari T, Kimura A, Ypma E, Toneatto D, Dull P. 2010. Tolerability of a three-dose schedule of an investigational, multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial, p 168. Abstr. 17th International Pathogenic Neisseria Conference (IPNC), Banff, Alberta, Canada.
8. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, Oster P, Miller E, Pollard AJ. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51: 1127-1137.
9. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29:e71-e79.
10. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Arico B, Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, Granoff DM, Caugant DA, Pizza M, Rappuoli R, Mora M. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195:1445-1454.
11. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799.
12. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, Santini L, Biolchi A, Seib KL, Giuliani MM, Donnelly JJ, Berti F, Savino S, Scarselli M, Costantino P, Kroll JS, O'Dwyer C, Qiu J, Plaut AG, Moxon R, Rappuoli R, Pizza M, Arico B. 2010. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc. Natl. Acad. Sci. U. S. A. 107:3770-3775.
13. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of proteinbased vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:19490-19495.
14. Goldschneider I, Gotschlich EC, Artenstein MS. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
15. Goldschneider I, Gotschlich EC, Artenstein MS. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1327-1348.
16. Gotschlich EC, Goldschneider I, Artenstein MS. 1969. Human immunity to the meningococcus. IV. Immunogenicity of group A and group Cmeningococcal polysaccharides in human volunteers. J. Exp. Med. 129: 1367-1384.
17. Gotschlich EC, Goldschneider I, Artenstein MS. 1969. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J. Exp. Med. 129:1385-1395.
18. Donnelly J, Medini D, Giuliani MM, Boccadifuoco G, Stella M, Frosi G, Comanducci M, Bambini S, Muzzi A, Pizza M, Rappuoli R, Findlow J, Borrow R, Gilchrist S, Thompson D, Ledroit M, Hong E, Taha MK, Abad R, Vazquez J, Mastrantonio P, Stefanelli P, Fazio C, Carannante A, Oksnes J, Caugant DA, Claus H, Vogel U. 2011. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci, p 17-18. Abstr. 11th European Monitoring Group on Meningococci Congress, Ljubljana, Slovenia.
19. Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseth SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW. 2011. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 29: 4739-4744
20. Metruccio MM, Pigozzi E, Roncarati D, Berlanda Scorza F, Norais N, Hill SA, Scarlato V, Delany I. 2009. A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog. 5:e1000710. doi: 10.1371/journal.ppat.1000710.
21. Perera IC, Lee YH, Wilkinson SP, Grove A. 2009. Mechanism for attenuation of DNA binding by MarR family transcriptional regulators by small molecule ligands. J. Mol. Biol. 390:1019-1029.
22. Takahama U, Oniki T, Murata H. 2002. The presence of 4-hydroxyphenylacetic acid in human saliva and the possibility of its nitration by salivary nitrite in the stomach. FEBS Lett. 518:116-118.
23. Fagnocchi L, Pigozzi E, Scarlato V, Delany I. 2012. In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva. J. Bacteriol. 194:460-474.
24. Litt DJ, Savino S, Beddek A, Comanducci M, Sandiford C, Stevens J, Levin M, Ison C, Pizza M, Rappuoli R, Kroll JS. 2004. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J. Infect. Dis. 190:1488-1497.
25. Ieva R, Roncarati D, Metruccio MM, Seib KL, Scarlato V, Delany I. 2008. OxyR tightly regulates catalase expression in Neisseria meningitidis through both repression and activation mechanisms. Mol. Microbiol. 70: 1152-1165.
26. Niimi, Y, Kambara H, Matsui T, Yoshioka D, Fukuyama H. 2006. Real-space imaging of alternate localization and extension of quasi-twodimensional electronic states at graphite surfaces in magnetic fields. Phys. Rev. Lett. 97:236804. doi:10.1103/PhysRevLett.97.236804.
27. Delany I, Ieva R, Alaimo C, Rappuoli R, Scarlato V. 2003. The ironresponsive regulator fur is transcriptionally autoregulated and not essential in Neisseria meningitidis. J. Bacteriol. 185:6032-6041.
28. Brier S, Fagnocchi L, Donnarumma D, Scarselli M, Rappuoli R, Nissum M, Delany I, Norais N. 2012. Structural insight into the mechanism of DNA-binding attenuation of the neisserial adhesin repressor NadR by the small natural ligand 4-hydroxyphenylacetic acid. Biochemistry 51:6738-6752.
29. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. 2009. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30:2785-2791.
30. Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, Findlow J, Hoiby EA, Rosenqvist E, Balmer P, Martin D. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12:970-976.
31. Moe GR, Tan S, Granoff DM. 1999. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun. 67: 5664-5675.
32. Mani AR, Ippolito S, Moreno JC, Visser TJ, Moore KP. 2007. The metabolism and dechlorination of chlorotyrosine in vivo. J. Biol. Chem. 282:29114-29121.
33. Granoff DM, Moe GR, Giuliani MM, Adu-Bobie J, Santini L, Brunelli B, Piccinetti F, Zuno-Mitchell P, Lee SS, Neri P, Bracci L, Lozzi L, Rappuoli R. 2001. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J. Immunol. 167:6487-6496.
34. Jacobsson S, Molling P, Olcen P. 2009. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine 27:5755-5759.
35. Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, Rappuoli R, Pizza M, Arico B. 2005. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol. Microbiol. 55:687-698.
36. Mazzon C, Baldani-Guerra B, Cecchini P, Kasic T, Viola A, de Bernard M, Arico B, Gerosa F, Papini E. 2007. IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J. Immunol. 179:3904-3916.
37. Franzoso S, Mazzon C, Sztukowska M, Cecchini P, Kasic T, Capecchi B, Tavano R, Papini E. 2008. Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA). J. Leukoc. Biol. 83:1100-1110.
38. Tavano R, Franzoso S, Cecchini P, Cartocci E, Oriente F, Arico B, Papini E. 2009. The membrane expression of Neisseria meningitidis adhesin A (NadA) increases the proimmune effects of MenB OMVs on human macrophages, compared with NadA- OMVs, without further stimulating their proinflammatory activity on circulating monocytes. J. Leukoc. Biol. 86:143-153.
39. Cecchini P, Tavano R, Polverino de Laureto P, Franzoso S, Mazzon C, Montanari P, Papini E. 2011. The soluble recombinant Neisseria meningitidis adhesin NadA(Delta351-405) stimulates human monocytes by binding to extracellular Hsp90. PLoS One 6:e25089. doi:10.1371/journal .pone.0025089.
40. Fukuyama N, Ichimori K, Su Z, Ishida H, Nakazawa H. 1996. Peroxynitrite formation from activated human leukocytes. Biochem. Biophys. Res. Commun. 224:414-419.